Table 1.

Demographics and HIV diagnosis and ART initiation among PLHIV in China 1 January 2015 to 31 December 2019

	Total	Before treat-all	After treat-all	P value
Total number in study period	75,516	19,938	55,578
Gender (%)				< 0.001
Male	63,279 (83.8%)	16,970 (85.1%)	46,309 (83.3%)
Female	12,237 (16.2%)	2968 (14.9%)	9269 (16.7%)
Age, years (%)				< 0.001
Median (IQR)	39 (28–53)	36 (27–49)	40 (28–54)
0–25	13,525 (17.9%)	4038 (20.3%)	9487 (17.1%)
26–35	21,959 (29.1%)	6468 (32.4%)	15,491 (27.9%)
36–50	19,961 (26.4%)	5526 (27.7%)	14,435 (26.0%)
> 50	20,071 (26.6%)	3906 (19.6%)	16,165 (29.1%)
Region (%)				< 0.001
Northern China	14,005 (18.5%)	4170 (20.9%)	9835 (17.7%)
Northeastern China	8238 (10.9%)	2197 (11.0%)	6041 (10.9%)
Southern China	13,238 (17.5%)	3862 (19.4%)	9376 (16.9%)
Southwestern China	37,163 (49.2%)	8793 (44.1%)	28,370 (51.0%)
Route of transmission (%)				< 0.001
Heterosexual	32,030 (42.4%)	7125 (35.7%)	24,905 (44.8%)
Homosexual	27,227 (36.1%)	8050 (40.4%)	19,177 (34.5%)
Others	16,259 (21.5%)	4763 (23.9%)	11,496 (20.7%)
Estimated time from infection to diagnosis (year)				< 0.001
Median (IQR)	5.9 (3.2–9.4)	5.3 (3.0–8.2)	6.1 (3.3–9.9)
Time from diagnosis to ART initiation (day)				< 0.001
Median (IQR)	26 (12–98)	41 (18–256)	22 (11–65)
CD4 at ART initiation (cells/μl)				< 0.001
Median (IQR)	247 (114–376)	277 (158–389)	235 (98–370)

ART Antiretroviral therapy, PLHIV People living with HIV, IQR Interquartile range. Before treat-all: 1 January 2015–31 May 2016. After treat-all: 1 June 2016–31 December 2019. Region was divided into Northern China (Hohhot, Shijiazhuang, Beijing and Tianjin), Northeastern China (Dalian and Shenyang), Southern China (Guangzhou and Shenzhen), Southwestern China (Chongqing and Dehong), and Eastern China (Nanjing)